Figure 1
Anti–CD19-CAR–transduced T-cell production and clinical treatment protocols. (A) PBMCs were stimulated with the anti-CD3 mAb OKT3 on day 0. The cells were transduced with gammaretroviruses encoding the anti-CD19 CAR on days 2 and 3. On day 10, a rapid expansion protocol was started, and the cells were ready for infusion on day 24. (B) Patients received 60 mg/kg cyclophosphamide chemotherapy daily for 2 days. Next, patients received 25 mg/m2 fludarabine chemotherapy daily for 5 days. One day later, the patients received a single infusion of anti–CD19-CAR–transduced T cells. Starting on the same day as the T-cell infusion, the patients received IV IL-2 every 8 hours.
